AKT1 and digestive system neoplasm: Loratadine, in combination with thioridazine may inhibit the rapamycin signaling pathway via phosphoinositide 3-kinase/Akt/mammalian target in gastrointestinal tumor [23] and effectively overcome immune evasion by suppressing CRC growth in a mouse model [24].